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Reminder to All Pharmacy Technicians
Pharmacy technicians must be certified beginning 
July 1, 2010, and must maintain both national certifi-
cation and their pharmacy technician registration with 
the Iowa Board of Pharmacy. All currently registered 
pharmacy technicians who have not provided the Board 
with documentation that they have attained national 
certification should have received a new registration 
certificate identifying the technician as a “technician 
trainee” with a registration expiration date of June 30, 
2010. Once a technician trainee attains certification, the 
individual must complete an application for registration 
as a certified technician and submit that application, fee, 
and supporting documents to the Board. Certified phar-
macy technicians will receive a registration certificate 
that identifies the technician as a “certified” technician.
Iowa Prescription Monitoring 
Program Update
As reported in the last issue of this Newsletter, the 
Iowa Prescription Monitoring Program (PMP) is fully 
operational.  Pharmacists may utilize “alerts” within the 
PMP program to notify other pharmacists and prescrib-
ing practitioners when a patient is identified for using 
multiple prescribers and multiple pharmacies to obtain 
controlled substances. Alerts may also be used when 
a patient is identified for presenting forged or altered 
prescriptions.
Requests that are submitted to the PMP program should 
identify the patient by last name, first name, and date 
of birth. Using those three criteria, and only those three 
criteria, usually provides an automatically processed 
report that is viewable within seconds of submitting the 
request. 
When submitting prescription data to the PMP pro-
gram, which includes prescriptions issued by physician 
assistants (PA), pharmacists are reminded to submit the 
Drug Enforcement Administration (DEA) number of 
the PA and not the DEA number of the PA’s supervising 
physician.
The Board encourages Iowa pharmacists and pre-
scribers to register for program access if they have not 
already done so. To register, please go to https://pmp
.iowa.gov/IAPMPWebCenter/ and click on the following 
line: “Not a User? Register to become a User.”  Questions 
or concerns should be directed to program administra-
tors Terry Witkowski or Debbie Jorgenson at 515/281-
5944 or via e-mail at terry.witkowski@iowa.gov or 
debbie.jorgenson@iowa.gov.
Board Action Spurs Record-Setting 
Federal Prosecution
In September 2003, the Iowa Board of Pharmacy took 
emergency disciplinary action against the Union Family 
Pharmacy in Dubuque, IA, and two pharmacists – Jack E. 
Huzl and Douglas W. Bouchey. This case later became a 
six-year criminal prosecution, which led to the conviction 
of 26 people in United States District Court – including 
19 doctors – and the forfeiture of more than $7 million 
in assets. “This federal prosecution resulted in the most 
defendants ever convicted in an Internet pharmacy case in 
the United States,” said US Attorney Matt Dummermuth 
on June 10, 2009, noting that the forfeiture was the largest 
ever in the northern district of Iowa. Federal authorities 
found evidence that Union Family Pharmacy had illegally 
dispensed more than a million prescription pain, diet, and 
psychiatric medications over a six-month period for two 
Florida-based Internet companies, Pharmacon Interna-
tional Corporation and Medical Web Services. Federal 
prosecutors said the two companies recruited doctors 
from around the country to review orders placed by cus-
tomers online. The prescriptions were filled without any 
medical examination or any contact between physicians 
and patients, prosecutors said. Between 2002 and 2004, 
the companies together issued about 500,000 prescrip-
tions for roughly 31 million dosages, authorities said. 
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Pharmaceutical Cargo Theft of Copaxone®
The Food and Drug Administration (FDA) Office of 
Criminal Investigations (OCI) reported that a shipment 
of approximately 14 pallets/994 cartons/5,962 packs of 
Copaxone® (glatiramer acetate) 20 mg, a non-controlled 
substance, was stolen during the week of April 13-17, 2009. 
The tractor trailer was recovered at a rest stop on the New 
Jersey Turnpike on April 20. Unfortunately the trailer was 
empty. Corporate security from Teva Pharmaceutical In-
dustries Ltd recalled the remainder of lot #P53159, which 
has an expiration date of January 2011. If that particular 
product is found anywhere or offered for sale, it would be 
the stolen product.
Copaxone is a unique product and is used only to treat 
patients suffering from multiple sclerosis. If the product is 
not stored below 74º F and out of the sunlight, it becomes 
ineffective and may not be safe for use. 
Immediately notify the FDA OCI if you are contacted by 
individuals offering to sell this product, if you have pur-
chased this product, or if you know of anyone that may be 
involved with the theft and the distribution of this product. 
Any information should be provided to Special Agent 
Gregg Goneconto or Special Agent Nancy Kennedy at 
OCI Headquarters (800/551-3989), or at www.fda.gov/oci/
contact.html. 
Failed Check System Leads to Pharmacist’s 
No Contest Plea for Involuntary Manslaughter
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency that 
analyzes medication errors, near misses, and 
potentially hazardous conditions as reported 
by pharmacists and other practitioners. ISMP 
then makes appropriate contacts with companies and regu-
lators, gathers expert opinion about prevention measures, 
and publishes its recommendations. To read about the risk 
reduction strategies that you can put into practice today, 
subscribe to ISMP Medication Safety Alert!® Community/
Ambulatory Care Edition by visiting www.ismp.org. ISMP is 
a federally certified Patient Safety Organization, providing 
legal protection and confidentiality for submitted patient 
safety data and error reports. ISMP is also a FDA MedWatch 
partner. Call 1-800-FAIL-SAF(E) to report medication er-
rors to the ISMP Medication Errors Reporting Program or 
report online at www.ismp.org. ISMP address: 200 Lakeside 
Dr, Suite 200, Horsham, PA 19044. Phone: 215/947-7797. 
E-mail: ismpinfo@ismp.org.
A former Ohio pharmacist will plead no contest to invol-
untary manslaughter of a two-year-old child who died in 
2006 as a result of a chemotherapy compounding error.1 The 
pharmacy board revoked the pharmacist’s license and, after 
holding a criminal investigation, a grand jury indicted him on 
charges of reckless homicide and involuntary manslaughter. 
The pharmacist faces up to five years in prison.
Prosecutors hold the pharmacist responsible for the 
toddler’s death because he oversaw the preparation of her 
chemotherapy. A pharmacy technician mistakenly prepared 
the infusion using too much 23.4% sodium chloride. The 
infusion was administered to the child, who died three days 
later. 
Though we cannot shed more light on the root causes 
of the error, our experiences with analyzing other errors 
strongly suggest that underlying system vulnerabilities 
played a role. Compounding the solution from scratch is 
error prone. Communication failures between technicians 
and pharmacists, IV compounder-related failures, inadequate 
documentation of the exact products and amounts of addi-
tives, and other system issues have contributed to numerous 
fatal errors. ISMP has also received reports of compounding 
errors and subsequent failed double-checks due to adverse 
performance-shaping factors such as poor lighting, clutter, 
noise, and interruptions. In fact, in this particular case, news 
reports suggest that the pharmacist felt rushed, causing him 
to miss any flags that may have signaled an error.2 
Without minimizing the loss of life in this case, we con-
tinue to be deeply concerned about the criminalization of 
human errors in health care. Safety experts including ISMP 
advocate for a fair and just path for individuals involved 
in adverse events, arguing that punishment simply because 
the patient was harmed does not serve the public interest. 
Its potential impact on patient safety is enormous, sending 
the wrong message to health care professionals about the 
importance of reporting and analyzing errors. All profession-
als are fallible human beings destined to make mistakes and 
drift away from safe behaviors as perceptions of risk fade 
when trying to do more in resource-strapped professions. 
When warranted, licensing boards can protect patients from 
reckless or incompetent actions of health care practitioners 
by limiting or revoking licenses. 
While the law clearly allows for the criminal indictment 
of health care professionals who make harmful errors, the 
greater good is served by focusing on system issues that al-
low tragedies like this to happen. Focusing on the easy target, 
the pharmacist, makes us wonder whether any regulatory or 
accreditation agency is ensuring that all hospitals learn from 
this event and adjust their systems to prevent the same type 
of error. If not, the death of this little girl is a heartbreaking 
commentary on health care’s inability to truly learn from 
mistakes so that they are not destined to repeat.     
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NABP Wins ASAE’s 2009 Associations 
Advance America Award of Excellence
In recognition of its efforts for educating patients on the 
potential dangers of buying medications online and empow-
ering patients to make informed choices through its Internet 
Drug Outlet Identification program, the National Associa-
tion of Boards of Pharmacy® (NABP®) recently received the 
2009 Associations Advance America (AAA) Award from the 
American Society of Association Executives (ASAE) and the 
Center for Association Leadership in Washington, DC. 
Launched in May 2008, the Internet Drug Outlet Iden-
tification program reviews and monitors Web sites selling 
prescription medications and distinguishes those sites that do 
and do not meet state and federal laws and/or NABP patient 
safety and pharmacy practice standards. Internet drug outlets 
that appear to be operating in conflict with program criteria, 
such as dispensing drugs that are unapproved and potentially 
counterfeit, frequently without a valid prescription, pose a 
significant risk to the public health. Such findings underscore 
the importance of this project and other efforts to contain 
the Web-based distribution of prescription drugs within the 
appropriate legal and regulatory framework.
“NABP is honored to have been selected for this presti-
gious award for our efforts to bring about positive change,” 
says NABP President Gary A. Schnabel, RN, RPh. “This 
program represents a strong demonstration of our commit-
ment to the NABP mission of assisting the state boards of 
pharmacy in protecting the public health.”
NABP is one of only 21 organizations nationally to receive 
an award of excellence in the first round of ASAE’s 2009 
AAA Award program, an award that recognizes associa-
tions that propel America forward with innovative projects 
in education, skills training, standards setting, business and 
social innovation, knowledge creation, citizenship, and 
community service.
Consumer Directed Questions and 
Answers about FDA’s Initiative Against 
Contaminated Weight-Loss Products 
FDA has developed questions and answers to help con-
sumers, health care practitioners, and the general public 
understand FDA’s actions regarding weight-loss products 
contaminated with various prescription drugs and chemicals. 
Many of these products are marketed as dietary supplements. 
Unfortunately, FDA cannot test and identify all weight-loss 
products on the market that have potentially harmful con-
taminants in order to ensure their safety. FDA laboratory 
tests have revealed the presence of sibutramine, fenproporex, 
fluoxetine, bumetanide, furosemide, phenytoin, rimonabant, 
cetilistat, and phenolphthalein in weight-loss products being 
sold over-the-counter. Enforcement actions and consumer 
advisories for unapproved products only cover a small 
fraction of the potentially hazardous weight-loss products 
marketed to consumers on the Internet and at some retail 
establishments.
Pharmacists can advise patients to help protect themselves 
from harm by consulting with their health care professional 
before taking dietary supplements to treat obesity or other 
diseases. Patients should be advised of the following signs 
of health fraud:
 ♦ Promises of an “easy” fix for problems like excess weight, 
hair loss, or impotency
 ♦ Claims such as “scientific breakthrough,” “miraculous 
cure,” “secret ingredient,” and “ancient remedy” 
 ♦ Impressive-sounding terms, such as “hunger stimulation 
point” and “thermogenesis” for a weight-loss product
 ♦ Claims that the product is safe because it is “natural” 
 ♦ Undocumented case histories or personal testimonials by 
consumers or doctors claiming amazing results
 ♦ Promises of no-risk, money-back guarantees
More information is available on the FDA Web site at 
www.fda.gov/Drugs/ResourcesForYou/Consumers/Questions
Answers/ucm136187.htm.
Jury Trial Set for Doctor Charged with 
Bringing Misbranded Foreign Cancer 
Drugs into US
A jury trial to hear the case of USA v. Vinod Chandrashekm 
Patwardhan, MD was set to begin on April 21, 2009, in the
US District Court for the Central District of California. 
Patwardhan, an Upland, CA doctor who specialized in treat-
ing cancer patients, was arrested in August 2008 by federal 
authorities after being charged with introducing foreign 
misbranded drugs into interstate commerce. These drugs 
reportedly were sometimes diluted when they were admin-
istered to his patients, according to a news release issued by 
Thomas P. O’Brien, US attorney for the Central District of 
California, on the day of the arrest. The charge of delivering 
misbranded drugs into interstate commerce with the intent 
to defraud or mislead carries a penalty of up to three years 
in federal prison.
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Along with the doctors, those convicted in Iowa included 
corporate officers, physician recruiters, and a pharmacist. 
Twelve other doctors either entered into agreements to 
avoid prosecution or were prosecuted in other states.
In Memory Of . . . 
Debra C. “Debi” Ringgen-
berg. Debi Ringgenberg passed 
away on June 2, 2009, at the age 
of 55. A 1977 graduate of the 
University of Iowa College of 
Pharmacy, Debi worked exten-
sively in retail pharmacy in both 
Nebraska and Iowa and as a staff 
pharmacist at Mercy Medical 
Center in Sioux City. She worked 
for the Iowa Board of Pharmacy 
as an inspector, investigator, and 
compliance officer from November 18, 2002 to March 27, 
2007. During that time she covered the northwest corner 
of the state. She was instrumental in handling Internet 
drug investigations and in helping the Board develop rules 
for sterile compounding. In April 2007, Debi became the 
executive director of the Missouri Board of Pharmacy, a 
position she held until the summer of 2008. Debi had an 
indomitable spirit. Her passions included skiing and ten-
nis. The Board extends its sincerest sympathy to Debi’s 
children, Jeff and Jennifer.
Janet A. “Jan” Horrigan. Jan 
Horrigan passed away on March 
30, 2009, at the age of 73. Jan 
worked for the Iowa Board of 
Pharmacy for 25 years and served 
as the personal secretary to three 
executive directors. She was also 
responsible for processing new 
pharmacist license applications 
and for administering the intern 
program. She retired at the end of 
1998. Jan had a great sense of humor and was loved by all. 
The Board extends its sincerest sympathy to Jan’s loving 
companion, Ed Bartine; her children – John, Judy, and 
Teri; and her six grandchildren and one great-grandchild.
With the passing of Debi and Jan, we have lost two dear 
friends and colleagues. Their record of involvement in the 
pharmacy profession and their respective communities is 
a legacy of distinguished service and accomplishment. 
Their contributions to the Iowa Board of Pharmacy will 
long be remembered
Board Meeting Calendar
The following meeting dates have been set for future 
Board meetings:
 ♦ September 22-23, 2009
 ♦ November 17-18, 2009
Dates are subject to change. All meetings will be held 
at the Board office in Des Moines, IA. Please visit the 
Board’s Web site at www.state.ia.us/ibpe or call 515/281-
5944 to confirm meeting dates.
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